adoptive cell therapy with tumor-infiltrating lymphocytes in advanced melanoma patients
Clicks: 200
ID: 232514
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
200 views
18 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #67 of 150 articles by views in journal of photochemistry and photobiology b, biology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 150 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). This monocenter retrospective study was undertaken to evaluate the efficacy and safety of this treatment of patients with advanced melanoma. All advanced melanoma patients treated with TILs using the same TIL expansion methodology and same treatment interleukin-2 (IL-2) regimen between 2009 and 2012 were included. After sterile intralesional excision of a cutaneous or subcutaneous metastasis, TILs were produced according to a previously described method and then infused into the patient who also received a complementary subcutaneous IL-2 regimen. Nine women and 1 man were treated for unresectable stage IIIC (n=4) or IV (n=6) melanoma. All but 1 patient with unresectable stage III melanoma (1st line) had received at least 2 previous treatments, including anti-CTLA-4 antibody for 4. The number of TILs infused ranged from 0.23 × 109 to 22.9 × 109. Regarding safety, no serious adverse effect was reported. Therapeutic responses included a complete remission, a partial remission, 2 stabilizations, and 6 progressions. Among these 4 patients with clinical benefit, 1 is still alive with 9 years of follow-up and 1 died from another cause after 8 years of follow-up. Notably, patients treated with high percentages of CD4 + CD25 + CD127lowFoxp3+ T cells among their TILs had significantly shorter OS. The therapeutic effect of combining TILs with new immunotherapies needs further investigation.
| Reference Key |
saint-jean2018journaladoptive
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Mélanie Saint-Jean;Anne-Chantal Knol;Christelle Volteau;Gaëlle Quéreux;Lucie Peuvrel;Anabelle Brocard;Marie-Christine Pandolfino;Soraya Saiagh;Jean-Michel Nguyen;Christophe Bedane;Nicole Basset-Seguin;Amir Khammari;Brigitte Dréno |
| Journal | journal of photochemistry and photobiology b, biology |
| Year | 2018 |
| DOI |
10.1155/2018/3530148
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.